Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
A 'disoriented' Pain Therapeutics flips out after FDA rejects appeal on Remoxy
7 years ago
R&D
Amgen, Sanofi back a round for real-world evidence platform tech; Daiichi Sankyo's pexidartinib secures speedy FDA ...
7 years ago
News Briefing
Here come the 2019 unicorns: Alector, Gossamer set to launch IPOs donning $1B-plus market caps
7 years ago
Financing
The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance
7 years ago
Discovery
After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck
7 years ago
Pharma
As Herceptin biosimilars eat into Roche sales, Swiss drugmaker makes case for expanded Kadcyla use
7 years ago
Pharma
In a field littered with failures, positive data prompt speedy US, EU review of AstraZeneca's long-acting RSV drug
7 years ago
Pharma
Shakeup at the top of FDA’s biosimilars division as Leah Christl departs for Amgen
7 years ago
People
Pharma
Flying solo for a change, Sanofi says isatuximab scored an important success in first PhIII myeloma study
7 years ago
R&D
Baeuerle-backed Cullinan grows its pipeline of portfolio plays, adopts a new cancer drug with eye to clinical ...
7 years ago
Pharma
Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?
7 years ago
R&D
Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug
7 years ago
News Briefing
Keto in a pill? Jim Mellon debuts anti-aging joint venture with the Buck dedicated to inducing ketosis
7 years ago
Startups
Peter Diamandis' right hand man Sergey Young wants to reverse aging via his $100M Longevity Vision Fund
7 years ago
People
Financing
'Most feared' activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B ...
7 years ago
People
Deals
Evolus celebrates greenlight for Botox rival while Allergan counterattacks with a complaint of stolen trade secrets
7 years ago
Pharma
Medicxi bankrolls the launch of a pair of biotech twins focused on orexins for narcolepsy and more
7 years ago
Financing
Startups
GenSight’s second LHON gene therapy PhIII stumbles out of the gate — just like the first time
7 years ago
R&D
Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461
7 years ago
Pharma
Pharma, we have a problem: New drugs can't cover the cost of Big Pharma's failures
7 years ago
R&D
Biotech Voices
EMA endorses Teva's migraine drug; Disaster prone CTI BioPharma rescinds EU application for pacritinib
7 years ago
News Briefing
Richard Pascoe takes the helm at Histogen; Lonza COO steps up at CEO Richard Ridinger retires
7 years ago
Peer Review
Playing hardball, Bristol-Myers bought out a battered Celgene with last-minute terms sweetened in its own favor
7 years ago
Deals
With a deeper discount in place, NICE now ready to endorse use of Novartis' Kymriah in adult lymphoma patients
7 years ago
R&D
First page
Previous page
977
978
979
980
981
982
983
Next page
Last page